ClinicalTrials.gg
CompletedNCT05958784Updated Dec 6, 2024

PKU Carriers Trial (Pilot Study): Impact on Cognition, Mental Health, Blood Pressure and Metabolism

An interventional study of L-Phenylalanine in Autosomal Recessive Disorder (Genetic Carriers of PKU), sponsored by University of Guelph. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by University of Guelph · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 77 studies in Genetic Diseases, Inborn with a site in Canada — 20 open to participants now, 27 under way, 7 of them phase 3. Genetic Diseases, Inborn · Canada.

Enrollment
60th of 63
7 · median 60
Started
2023
with 3 others
No phase
8 of 77
2 open now
Registered
57th of 77
by date

Among the 77 studies in Genetic Diseases, Inborn with a site in Canada, this one is the 60th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2023, is one of 8 with no phase, and was the 57th registered.

Genetic Diseases, Inborn

585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

20 of the 77 studies in Genetic Diseases, Inborn with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Genetic Diseases, Inborn with a site in Canada, or all of them as a file.
02

Study summary

This is a clinical intervention pilot/feasibility study of PKU carriers (cases) and non-carriers (controls). Upon completing the informed consent process, participants will complete baseline measures of chronic mental health prior to the intervention (PHQ-9, GAD-7, BIS-Brief). Participants will attend the Human Nutraceutical Research Unit (HNRU) at the University of Guelph, fasted, and first undergo baseline measures of cognition and acute mental health (mood) and provide samples or saliva, urine and dried blood spots to evaluate phenylalanine (Phe), tyrosine (Tyr) and their metabolites (PAH pathway functioning). Participants will also complete a brief questionnaire which will include age, sex, ethnicity, income, weight and height (measured using a stadiometer and calibrated weigh scale), and confirmation that participants arrived to the lab fasted (i.e. have only had water to drink and no other foods/beverages prior to analyses). Blood pressure will also be measured at baseline. Following baseline tests, participants will consume a pure L-Phe supplement dosed at 100 mg/kg mixed into 250 mL water with 1 tsp white sugar. Blood pressure will be repeated at 1-hour post-L-Phe consumption. Two-hours postprandial, participants will repeat the cognitive tests and acute mental health (mood) assessment, blood pressure measurement and provide follow-up saliva, urine and dried blood spot samples. Participants will also be asked to report any side effects they experienced with the L-Phe consumption.

03

Conditions studied

  • Autosomal Recessive Disorder (Genetic Carriers of PKU)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known carrier or non-carrier of PKU
  • At least 18 years of age
  • Comfortable fasting the morning of the study (no food or drink other than water)

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with: PKU, severe neurodegenerative conditions affecting cognition (e.g. Alzheimer's, Parkinson's, dementia), melanoma, hypertension, liver disease and/or kidney disease
  • Taking a Monoamine Oxidase Inhibitor anti-depressant
  • Pregnant or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Genetic Carriers and Non-Carriers of PKU

    Dietary Supplement: L-Phenylalanine

Interventions

06

What researchers measure

Primary outcomes

  1. Stop Signal Reaction Time (Response Inhibition)

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

Secondary outcomes

  1. Working Memory

    N-Back Test Outcome

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  2. Stop Signal Delay

    Stop Signal Task Outcome

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  3. Individual Coefficient of Variance (Variability in Reaction Times)

    Stop Signal Task Outcome

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  4. Phenylalanine Levels

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  5. Tyrosine Levels

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  6. Phenylalanine Metabolites: e.g.phenylethylamine, tyramine, phenylpyruvate, others

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  7. Tyrosine Metabolites: e.g. L-DOPA, dopamine, norepinephrine, epinephrine, p-hydroxyphenylpyruvate, homogentisic acid, fumarate, others

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  8. Mood

    Profile of Mood States (POMS) Outcome

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

  9. Blood Pressure

    Systolic and Diastolic

    Time frame: Change from baseline to 1-hour and 2-hours post L-Phe supplementation

Other outcomes

  1. Chronic Anxiety

    GAD-7 Outcome

    Time frame: Baseline

  2. Chronic Depression

    PHQ-9 Outcome

    Time frame: Baseline

  3. Impulsivity

    BIS-Brief Outcome

    Time frame: Baseline

  4. Trial-by-trial analysis

    To be conducted if there are significant findings from the four main stop signal task outcomes

    Time frame: Change from baseline to 2-hours post L-Phe supplementation

07

Study locations

1 site
  • University of Guelph
    Guelph, Ontario N1G 2W1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Dec 2023, 5 months.

Of 64 non-industry interventional studies with no phase under Genetic Diseases, Inborn, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's 5 months is below that.

Counting every sponsor, half of 66 studies reached it within 41 months; a quarter within 22 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 25, 2023
StartActual
Jul 1, 2023
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2023
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05958784
Lead sponsor
University of Guelph
Collaborators
McMaster University
Responsible party
Justine Keathley (Assistant Professor, University of Guelph) — Principal investigator
First posted
Jul 25, 2023
Start date
Jul 1, 2023
Primary completion
Dec 1, 2023
Completion
Dec 1, 2023
Last update
Dec 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenylalanine

Start the discussion